|
Pipeline / Clinical Trials
Product Development Pipeline |
Join the Epidermolysis Bullosa Wound Healing Study
ONLY 6 SLOTS REMAIN - Find out how. |
RegeneRx has initiated 3 clinical trials to develop 3 product candidates in our pipeline. The product candidates are all Tβ4-based peptides and have been formulated to optimize the clinical potential in various indications, all with unmet medical needs.
| RGN-352 Injectable |
|
Acute M.I.
(Phase 2 currently
on clinical hold)* |
 |
| Multiple Sclerosis |
 |
| RGN-259 Eye Drops |
|
N. Keratitis
(Compassionate Use) |
 |
Dry Eye
(Physician Sponsored) |
 |
| Dry Eye |
 |
| Diabetic Vitrectomy |
 |
| RGN-457 Inhalation |
|
| Cystic Fibrosis |
 |
| Bronchiectasis |
 |
| Cosmeceutical Peptides |
 |
* In March 2011 the FDA placed a “clinical hold” on our Phase 2 AMI trial due to cGMP issues at a contract manufacturer’s site formulating RGN-352. The timing for the resumption of this trial is unclear. The reader is referred to our press releases dated March 16 and April 14, 2011.
|
